JPS5665829A - Antitumor agent - Google Patents

Antitumor agent

Info

Publication number
JPS5665829A
JPS5665829A JP14215379A JP14215379A JPS5665829A JP S5665829 A JPS5665829 A JP S5665829A JP 14215379 A JP14215379 A JP 14215379A JP 14215379 A JP14215379 A JP 14215379A JP S5665829 A JPS5665829 A JP S5665829A
Authority
JP
Japan
Prior art keywords
antibody
antitumor
purity
tumor
purified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP14215379A
Other languages
Japanese (ja)
Other versions
JPS6256137B2 (en
Inventor
Chikao Yoshikumi
Takami Fujii
Masahiko Fujii
Kenichi Matsunaga
Yoshiharu Oguchi
Koichi Niimura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kureha Corp
Original Assignee
Kureha Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kureha Corp filed Critical Kureha Corp
Priority to JP14215379A priority Critical patent/JPS5665829A/en
Priority to US06/103,474 priority patent/US4315851A/en
Priority to SE7910483A priority patent/SE7910483L/en
Priority to PH23447A priority patent/PH16902A/en
Priority to CH11501/79A priority patent/CH655010A5/en
Priority to FR797932054A priority patent/FR2445149B1/en
Priority to GB7944494A priority patent/GB2038836B/en
Priority to DE2952690A priority patent/DE2952690C2/en
Priority to IT28464/79A priority patent/IT1127324B/en
Publication of JPS5665829A publication Critical patent/JPS5665829A/en
Priority to US06/321,486 priority patent/US4401592A/en
Priority to SE8406511A priority patent/SE8406511L/en
Priority to SE8406510A priority patent/SE8406510D0/en
Publication of JPS6256137B2 publication Critical patent/JPS6256137B2/ja
Granted legal-status Critical Current

Links

Abstract

NEW MATERIAL:A substance obtained by subjecting a high-purity antibody to a tumor antigen, prepared by purification through affinity chromatography, and an antitumor antimetabolite having at least one amino or carboxyl group to amide bonding.
EXAMPLE: An amide bond substance of a high-purity immunoglobulin induced from an antigen of human cancer, e.g., sarcoma 180, Sato's lung cancer, leukemia L-1210, Ehrlich cancer, etc. and purified, and cytarabine, 8-azaguanine, 5-fluorouracil, etc.
USE: An antitumor agent. Since the agent is bonded to a high-purity antibody to a tumor antigen, it can be transferred efficiently to tumor parts of the body, and it can exhibit an antitumor effect selectively. Consequently, side effects to the normal cell occur slightly.
PROCESS: A tumor cell is injected hypodermically to an animal, which is immunized to give an antibody which is purified. The highly purified antibody and an antitumor antimetabolite are subjected to amide bonding.
COPYRIGHT: (C)1981,JPO&Japio
JP14215379A 1978-12-29 1979-11-02 Antitumor agent Granted JPS5665829A (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP14215379A JPS5665829A (en) 1979-11-02 1979-11-02 Antitumor agent
US06/103,474 US4315851A (en) 1978-12-29 1979-12-14 Pharmaceutical composition having antitumor activity
SE7910483A SE7910483L (en) 1978-12-29 1979-12-19 PHARMACEUTICAL COMPOSITION WITH TUMOR INHIBITION EFFECT
PH23447A PH16902A (en) 1978-12-29 1979-12-20 Pharmaceutical composition having anti-tumor activity
CH11501/79A CH655010A5 (en) 1978-12-29 1979-12-28 PHARMACEUTICAL ACTIVE SUBSTANCE WITH ANTITUM ORACTIVITY.
FR797932054A FR2445149B1 (en) 1978-12-29 1979-12-28 PHARMACEUTICAL COMPOSITION HAVING ANTI-TUMOR ACTIVITY
GB7944494A GB2038836B (en) 1978-12-29 1979-12-28 Antitumour substance
DE2952690A DE2952690C2 (en) 1978-12-29 1979-12-29 Antitumor substance, process for their preparation and pharmaceutical agent containing them
IT28464/79A IT1127324B (en) 1978-12-29 1979-12-31 Antitumour compsn. contg. high purity antibody
US06/321,486 US4401592A (en) 1978-12-29 1981-11-16 Pharmaceutical composition having antitumor activity
SE8406511A SE8406511L (en) 1978-12-29 1984-12-20 PHARMACEUTICAL COMPOSITION WITH TUMOR INHIBITION EFFECT
SE8406510A SE8406510D0 (en) 1978-12-29 1984-12-20 PHARMACEUTICAL COMPOSITION WITH TUMOR INHIBITION EFFECT

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14215379A JPS5665829A (en) 1979-11-02 1979-11-02 Antitumor agent

Publications (2)

Publication Number Publication Date
JPS5665829A true JPS5665829A (en) 1981-06-03
JPS6256137B2 JPS6256137B2 (en) 1987-11-24

Family

ID=15308586

Family Applications (1)

Application Number Title Priority Date Filing Date
JP14215379A Granted JPS5665829A (en) 1978-12-29 1979-11-02 Antitumor agent

Country Status (1)

Country Link
JP (1) JPS5665829A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62142124A (en) * 1983-04-08 1987-06-25 Kureha Chem Ind Co Ltd Antitumor agent bonded with with human immunoglobulin

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01257331A (en) * 1987-12-10 1989-10-13 Fuji Electric Co Ltd Microwave matching apparatus and microwave matching

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4962194A (en) * 1972-05-10 1974-06-17
JPS5161640A (en) * 1974-09-20 1976-05-28 Searle & Co Koshuyozaino seizoho
JPS51144723A (en) * 1975-05-27 1976-12-13 Yeda Res & Dev Antiitumor agent

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4962194A (en) * 1972-05-10 1974-06-17
JPS5161640A (en) * 1974-09-20 1976-05-28 Searle & Co Koshuyozaino seizoho
JPS51144723A (en) * 1975-05-27 1976-12-13 Yeda Res & Dev Antiitumor agent

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62142124A (en) * 1983-04-08 1987-06-25 Kureha Chem Ind Co Ltd Antitumor agent bonded with with human immunoglobulin
JPH0611714B2 (en) * 1983-04-08 1994-02-16 呉羽化学工業株式会社 Human immunoglobulin-binding antitumor agent

Also Published As

Publication number Publication date
JPS6256137B2 (en) 1987-11-24

Similar Documents

Publication Publication Date Title
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
DK0458878T3 (en) New monoclonal antibody to a new antigen associated with human tumors
SG96535A1 (en) Pharmaceutical composition for the treatment or prevention of a malignant tumor
AU3125289A (en) Monoclonal antibodies directed against human tumor necrosis factor - receptor
CA2098021A1 (en) Composition Used as a Therapeutic Agent Against Chronic Viral Hepatic Diseases
EP0147283A3 (en) Immunomodulating medicine based on fe fragments of human igg
CA2000913A1 (en) Family of high affinity antibodies for cancer treatment
IT8319160A0 (en) PROCESS FOR THE SYNTHESIS OF PEPTIDES AND AMINO ACIDS BLOCKING AGENTS.
GR852541B (en)
JPS5665829A (en) Antitumor agent
JPS5665828A (en) Antitumor agent
ES556684A0 (en) A PROCEDURE FOR TREATING EFFECT CELLS THAT HAVE SURFACE RECEPTORS FOR THE FC REGION OF AN ANTIBODY
CA1017675A (en) Use of l-prolyl l-leucyl glycine amide to treat parkinson's disease
CA2308007A1 (en) Enhancer for antibody to lymphocytic tumors
FR2555755B1 (en) METHOD FOR DETERMINING HUMAN IMMUNOGLOBULINS WHICH ARE SPECIFIC TO HUMAN CANCER ANTIGENS AND APPLICATION OF THIS METHOD IN THE SERODIAGNOSIS OF PRIMITIVE TUMOR DISEASES
EP0254593A3 (en) Preparation and uses of interferon-gamma
FI92716C (en) New monoclonal antibodies to IFN-Omega, their methods of preparation and their use for the purification and detection of IFN-Omega
CA2002218A1 (en) Neoglycoproteins, the preparation and use thereof
CA2038030A1 (en) Synthetic peptides which contain sequences from factor viia, and the use thereof
IT1233005B (en) MONOCLONAL HUMAN ANTIBODY, THERAPEUTIC COMPOSITION THAT CONTAINS IT MOBILE LINE ABLE TO PRODUCE THE ANTIBODY, PROCEDURE FOR ITS PRODUCTION
FR2524315B1 (en) NOVEL ANTIGEN FOR THE RESEARCH OF BRUCELLAL SKIN HYPERSENSITIVITY, PARTICULARLY IN MAN, AND METHOD FOR PREPARING THE SAME
MatthewsA Secretion of a macrophage-activating factor distinct from interferon-y by human T cell clones
HK1013296A1 (en) Analogs of thymosin alpha 1
RU93004625A (en) METHODS OF TREATMENT, ANTI-TUMOR AGENTS
PH10473A (en) Use of l-propyl l-leucyl glycine amide to treat parkinson's disease